Alx Oncology Holdings (ALXO) Amortizatization of Intangibles (2022 - 2026)
Alx Oncology Holdings (ALXO) reported Amortizatization of Intangibles of $199000.0 for Q1 2026, down 62.17% on a YoY basis from $526000.0 in Q1 2025, and up 6.99% sequentially from $186000.0 in Q4 2025.
Alx Oncology Holdings (ALXO) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Alx Oncology Holdings (ALXO) has 5 years of Amortizatization of Intangibles data on file, last reported at $199000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles fell 62.17% year-over-year to $199000.0; the trailing twelve-month figure through Mar 2026 stood at $915000.0 (down 74.79% YoY), and the FY2025 full-year result was $1.2 million, down 73.33% from the prior year.
- Amortizatization of Intangibles advanced to $199000.0 in Q1 2026, from $186000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.9 million in Q4 2023 to a low of -$107000.0 in Q1 2022.
- A 5-year average of $795588.2 and a median of $684000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles jumped 41150.0% in 2023 and slumped 79.14% in 2025, its largest moves.
- Tracing ALXO's Amortizatization of Intangibles over 5 years: stood at $684000.0 in 2022, then soared by 175.0% to $1.9 million in 2023, then tumbled by 60.82% to $737000.0 in 2024, then plunged by 74.76% to $186000.0 in 2025, then grew by 6.99% to $199000.0 in 2026.
- Business Quant data shows ALXO's Amortizatization of Intangibles at $199000.0 in Q1 2026, $186000.0 in Q4 2025, and $219000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Alx Oncology Holdings | 211.40 Mn | 211.40 Mn | - | 199,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 199,000.00 |
| Mar 31, 2026 | 199,000.00 |
| Dec 31, 2025 | 186,000.00 |
| Dec 31, 2025 | 186,000.00 |
| Sep 30, 2025 | 219,000.00 |
| Sep 30, 2025 | 219,000.00 |
| Jun 30, 2025 | 311,000.00 |
| Jun 30, 2025 | 311,000.00 |
| Mar 31, 2025 | 526,000.00 |
| Mar 31, 2025 | 526,000.00 |
| Dec 31, 2024 | 737,000.00 |
| Dec 31, 2024 | 737,000.00 |
| Sep 30, 2024 | 1.05 Mn |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 1.55 Mn |
| Mar 31, 2024 | 1.55 Mn |
| Dec 31, 2023 | 1.88 Mn |
| Dec 31, 2023 | 1.88 Mn |